Key result
Contemporary randomized trials on optimal antithrombotic therapy for patients with heart valve prostheses are scarce, underscoring the need to redefine treatment strategies.
There is a critical need for contemporary evidence to redefine optimal antithrombotic strategies in patients with modern heart valve prostheses.
Answers are grounded in this paper and cite their sources.
Scarcity of contemporary RCTs leaves antithrombotic strategies for valve prostheses undefined; prospective trials needed to inform guidelines.
Heart valve prostheses carry a risk for thrombosis and require an antithrombotic strategy to prevent stroke, systemic embolism, and prosthetic valve thrombosis. Contemporary randomized trials to guide the clinician on the optimal anticoagulant treatment are scarce, and the validity of the historical data for current recommendations can be questioned in view of the changes in valve prostheses, the patient population, and antithrombotic therapies. This limited evidence from clinical trials translates into divergent recommendations from the different scientific societies on the optimal intensity of oral anticoagulation and on the indication for antiplatelet therapy. The availability of new antithrombotic agents and the unclear thrombotic risk of the currently used prostheses underscore the need to redefine antithrombotic treatment in patients with heart valve prostheses.
No takes yet. Share an insight, caveat, or question.
Hermans et al. (2012) conducted a review in Heart valve prostheses. Antithrombotic therapy was evaluated. Contemporary randomized trials on optimal antithrombotic therapy for patients with heart valve prostheses are scarce, underscoring the need to redefine treatment strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: